Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Epizyme, Inc. (EPZM : NSDQ)

• Company Description    Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers. Number of Employees: 250

• Price / Volume Information    Yesterday's Closing Price: $0.50 Daily Weekly Monthly 20 Day Moving Average: 1,715,005 shares Shares Outstanding: 164.88 (millions) Market Capitalization: $82.75 (millions) Beta: 1.28 52 Week High: $9.86 52 Week Low: $0.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.11% -23.42% 12 Week -67.41% -64.64% Year To Date -79.92% -76.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 TECHNOLOGY SQUARE - CAMBRIDGE,MA 02139 USA ph: 617-229-5872 fax: 617-349-0707 wslattery@w2ogroup.com http://www.epizyme.com

• General Corporate Information    Officers Robert B. Bazemore - President and Chief Executive Officer Paolo Tombesi - Chief Financial Officer Joseph Beaulieu - Corporate Controller and Treasurer Andrew R. Allen - Director Kenneth Bate - Director Peer Information Epizyme, Inc. (CORR.) Epizyme, Inc. (RSPI) Epizyme, Inc. (CGXP) Epizyme, Inc. (BGEN) Epizyme, Inc. (GTBP) Epizyme, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29428V104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 164.88 Most Recent Split Date: (:1) Beta: 1.28 Market Capitalization: $82.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.15 EPS Growth vs. Year Ago Period: 43.48% vs. Previous Quarter: 20.41% Sales Growth vs. Year Ago Period: 13.96% vs. Previous Quarter: -24.92% ROE 03/31/22 - - 12/31/21 - -2,459.33 09/30/21 - -432.91 ROA 03/31/22 - -73.85 12/31/21 - -72.76 09/30/21 - -68.16 Current Ratio 03/31/22 - 5.87 12/31/21 - 4.56 09/30/21 - 5.53 Quick Ratio 03/31/22 - 5.75 12/31/21 - 4.49 09/30/21 - 5.50 Operating Margin 03/31/22 - -616.85 12/31/21 - -671.02 09/30/21 - -779.45 Net Margin 03/31/22 - -614.08 12/31/21 - -671.02 09/30/21 - -779.45 Pre-Tax Margin 03/31/22 - -613.94 12/31/21 - -670.91 09/30/21 - -779.12 Book Value 03/31/22 - -0.15 12/31/21 - -0.54 09/30/21 - -0.20 Inventory Turnover 03/31/22 - 3.95 12/31/21 - 2.04 09/30/21 - 1.32 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - 95.12 12/31/21 - - 09/30/21 - 93.36

Powered by Zacks Investment Research ©